AU2001238346A1 - Modification of biopolymers for improved drug delivery - Google Patents
Modification of biopolymers for improved drug deliveryInfo
- Publication number
- AU2001238346A1 AU2001238346A1 AU2001238346A AU3834601A AU2001238346A1 AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1 AU 2001238346 A AU2001238346 A AU 2001238346A AU 3834601 A AU3834601 A AU 3834601A AU 2001238346 A1 AU2001238346 A1 AU 2001238346A1
- Authority
- AU
- Australia
- Prior art keywords
- biopolymers
- modification
- drug delivery
- improved drug
- improved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920001222 biopolymer Polymers 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18255800P | 2000-02-15 | 2000-02-15 | |
| US60182558 | 2000-02-15 | ||
| US21150800P | 2000-06-14 | 2000-06-14 | |
| US60211508 | 2000-06-14 | ||
| PCT/US2001/004925 WO2001060412A2 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001238346A1 true AU2001238346A1 (en) | 2001-08-27 |
Family
ID=26878197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001238346A Abandoned AU2001238346A1 (en) | 2000-02-15 | 2001-02-15 | Modification of biopolymers for improved drug delivery |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1263472A2 (en) |
| JP (1) | JP2003522806A (en) |
| AU (1) | AU2001238346A1 (en) |
| CA (1) | CA2400205A1 (en) |
| IL (1) | IL151024A0 (en) |
| WO (1) | WO2001060412A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0116803A (en) * | 2001-01-18 | 2004-02-17 | Merck Patent Gmbh | Bifunctional fusion proteins with glucocerebrosidase activity |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| WO2004060404A1 (en) * | 2002-12-27 | 2004-07-22 | Chugai Seiyaku Kabushiki Kaisha | Drug carrier |
| US7803386B2 (en) | 2003-06-05 | 2010-09-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
| CA2529486A1 (en) * | 2003-06-18 | 2004-12-23 | Nst Neurosurvival Technologies Ltd. | Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| JP2007509643A (en) * | 2003-10-10 | 2007-04-19 | ゲ・ミン・ルイ | Methods and compositions for growth of corneal endothelium and related cells on biopolymers and creation of artificial corneal grafts |
| US7625736B2 (en) | 2004-06-04 | 2009-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for preparing immunogenic conjugates |
| EP1790665B1 (en) | 2004-09-07 | 2014-11-05 | Chugai Seiyaku Kabushiki Kaisha | Process for producing water-soluble modified hyaluronic acid |
| JP5137814B2 (en) * | 2005-04-06 | 2013-02-06 | ジェンザイム・コーポレーション | Conjugation of PEG and polysialicosomal enzymes via acid labile linkers for therapeutic targeting |
| US20080206276A1 (en) | 2005-07-08 | 2008-08-28 | Michael Otto | Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections |
| PT2121713E (en) | 2007-01-18 | 2013-06-25 | Genzyme Corp | Oligosaccharides comprising an aminooxy group and conjugates thereof |
| EP2465542B1 (en) | 2008-12-16 | 2015-01-21 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| ES2635087T3 (en) | 2011-03-03 | 2017-10-02 | Chugai Seiyaku Kabushiki Kaisha | Hyaluronic acid derivative modified with amino carboxylic acid |
| WO2012140650A2 (en) | 2011-04-12 | 2012-10-18 | Hepacore Ltd. | Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof |
| KR102130864B1 (en) | 2012-09-05 | 2020-07-08 | 추가이 세이야쿠 가부시키가이샤 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto |
| KR102049568B1 (en) * | 2013-04-01 | 2019-11-27 | 삼성전자주식회사 | Composition for nucleic acid delivery containing hyaluronic acid |
| GB201602359D0 (en) * | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108440684A (en) * | 2018-03-22 | 2018-08-24 | 华侨大学 | A kind of NI-Cys-Alg self-assembled nanometers carrier and its preparation method and application |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0537299A1 (en) | 1990-03-29 | 1993-04-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US5169934A (en) | 1990-05-14 | 1992-12-08 | Anergen, Inc. | Intracellularly cleavable compounds |
| US6335434B1 (en) * | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
| CA2122717C (en) | 1991-11-08 | 2003-07-15 | David C. Anderson | Hemoglobins as drug delivery agents |
| US5902795A (en) | 1992-06-16 | 1999-05-11 | Trustees Of Tufts College | Oligosaccharides reactive with hyaluronan-binding protein and their methods of use |
| US5329029A (en) | 1992-11-05 | 1994-07-12 | Wan Barbara Y | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates |
| AU673057B2 (en) * | 1993-02-22 | 1996-10-24 | Abraxis Bioscience, Llc | Methods for (in vivo) delivery of biologics and compositionsuseful therefor |
| US5354853A (en) | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| EP0975370B9 (en) | 1997-05-21 | 2004-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US5932552A (en) | 1997-11-26 | 1999-08-03 | Keraplast Technologies Ltd. | Keratin-based hydrogel for biomedical applications and method of production |
-
2001
- 2001-02-15 IL IL15102401A patent/IL151024A0/en unknown
- 2001-02-15 WO PCT/US2001/004925 patent/WO2001060412A2/en not_active Ceased
- 2001-02-15 EP EP01910775A patent/EP1263472A2/en not_active Ceased
- 2001-02-15 CA CA002400205A patent/CA2400205A1/en not_active Abandoned
- 2001-02-15 AU AU2001238346A patent/AU2001238346A1/en not_active Abandoned
- 2001-02-15 JP JP2001559507A patent/JP2003522806A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2400205A1 (en) | 2001-08-23 |
| IL151024A0 (en) | 2003-02-12 |
| EP1263472A2 (en) | 2002-12-11 |
| WO2001060412A3 (en) | 2002-01-24 |
| JP2003522806A (en) | 2003-07-29 |
| WO2001060412A2 (en) | 2001-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001235009A1 (en) | Drug delivery apparatus | |
| AU2001269529A1 (en) | Medicine comprising dicyanopyridine derivative | |
| AU2001264887A1 (en) | Drug delivery device | |
| AU2001288388A1 (en) | Substance delivery system | |
| EP1455697A4 (en) | Vaginal delivery of drugs | |
| AU2002217979A1 (en) | Medicine feeder | |
| AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
| AU2001238346A1 (en) | Modification of biopolymers for improved drug delivery | |
| AU2002343555A1 (en) | Eutectic-based self-nanoemulsified drug delivery system | |
| AU2002353444A1 (en) | Integrated transdermal drug delivery system | |
| AU2001276860A1 (en) | Medicaments for chemotherapeutic treatment of disease | |
| AUPR573001A0 (en) | Lymphatic drug delivery system | |
| AU2001277171A1 (en) | Catheter for target specific drug delivery | |
| AU6887401A (en) | Delivery of remotely-ordered products | |
| AU2001232020A1 (en) | Floating drug delivery composition | |
| AU777185C (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
| AU2002360717A1 (en) | Controlled release dosage form having improved drug release properties | |
| AU2001270963A1 (en) | Transdermal drug delivery system | |
| AU2001232244A1 (en) | Drug comprising combination | |
| AU2001260089A1 (en) | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | |
| AU2002308649A1 (en) | Compositions and methods for enhancing drug delivery | |
| AU3926000A (en) | Methods and compositions for drug delivery | |
| AU2002222138A1 (en) | Drug delivery system | |
| AU2002212863A1 (en) | Stable pharmaceutical form of an anticancer drug | |
| AU2001244854A1 (en) | Local drug delivery |